ad

Alembic Pharma Analyst Review 2027: Profit Up 81% and Guidance Raised, Stock Runs Past Targets

19 Nov 2026 • 1:57 pm

Alembic Pharma Analyst Review 2027: Profit Up 81% and Guidance Raised, Stock Runs Past Targets

Alembic Pharmaceuticals Stock Snapshot (18 Nov 2026 close)

  • Current Market Price (CMP): ₹1,044.35
  • 52-Week High / Low: ₹1,075.00 / ₹635.80
  • Market Capitalisation: ₹20,512 crore
  • P/E Ratio vs Industry P/E: 24.4 vs 40.1
  • Latest Quarter (Q2 FY27) Revenue: ₹2,603 crore
  • Latest Quarter (Q2 FY27) Net Profit: ₹335 crore

Quick Answer: The Alembic Pharma analyst review 2027 shows a blowout quarter that pushed the stock past the last named target. Q2 FY27 revenue rose 36% to ₹2,603 crore and profit rose 81% to ₹335 crore, with EBITDA margin up to 22% from 17%. US sales jumped 77% to ₹910 crore and management raised FY27 revenue growth guidance to 20% to 25%. Motilal Oswal's Neutral call with an ₹845 target (August 2026) is now about 19% below the ₹1,044.35 price, so the Alembic Pharma share price target 2027 picture needs fresh broker updates.

The Alembic Pharma analyst review 2027 covers Alembic Pharmaceuticals, a Vadodara-based drug maker that sells generics in the US, branded medicines in India, active pharmaceutical ingredients and products in other export markets. Readers looking for an Alembic Pharma share price target 2027 should note that the stock rallied about 20% in a single day after the results.

Alembic Pharmaceuticals closed at ₹1,044.35 on 18 November 2026, about 3% below its 52-week high of ₹1,075 and about 64% above its low of ₹635.80. This Alembic Pharma analyst review 2027 covers the results, the guidance change and the Alembic Pharma stock outlook 2027.

Click Here – Get Free Investment Predictions

What Brokerages Say in the Alembic Pharma Analyst Review 2027

Brokerage Rating Target Price Date
Motilal Oswal Neutral ₹845 4 August 2026

Motilal Oswal kept a Neutral view after the June quarter, valuing the company at 17 times forward earnings for an ₹845 target. It noted that the cancer drug bosutinib had 180-day US exclusivity on two strengths until November 2026.

We could not verify a named brokerage target issued after the November results. The stock now trades about 24% above Motilal Oswal's level, so revised notes will be the next test for this Alembic Pharma analyst review 2027.

Q2 FY27 Results in the Alembic Pharma Analyst Review 2027

Metric Q2 FY27 Q2 FY26 Change
Revenue from operations ₹2,603 crore ₹1,910 crore Up 36%
EBITDA ₹578 crore ₹323 crore Up about 79%
EBITDA margin 22% 17% Up 5 points
Net profit ₹335 crore ₹184 crore Up 81%

Revenue rose 36% and net profit rose 81%, as the EBITDA margin widened to 22%. Compared with the June quarter, profit rose about 94% and revenue about 21%.

All four businesses grew in double digits. That broad growth, rather than one product alone, is the core finding of this Alembic Pharma analyst review 2027.

How Alembic Pharma Makes Money

Segment Q2 FY27 Revenue Growth
US business ₹910 crore Up 77%
India branded ₹725 crore Up 14%
Ex-US international ₹440 crore Up 12%
API ₹436 crore Up 39%
  • US business: the largest segment, boosted by new launches including bosutinib.
  • India branded: medicines sold to doctors, with specialty and animal health driving growth.
  • API: active ingredients sold to other drug makers.
  • Ex-US exports: sales to Europe, emerging markets and other regions.

FY26 revenue was about ₹7,399 crore with profit of about ₹671 crore. Within the US business, management said generics grew 72% and the base portfolio grew 23% excluding new launches. These figures shape this Alembic Pharma analyst review 2027.

A 180-day exclusivity period lets the first generic seller earn high prices before rivals enter. Bosutinib's exclusivity ends in November 2026, so management factored some normalisation into its raised guidance. How much US sales hold up after that is the biggest single question for the coming quarters.

The company is also expanding its India specialty portfolio. India branded sales rose 14% against a historical growth rate of about 6% a year from FY22 to FY26, and total prescriptions rose to 137.6 million in the year to September 2026 from 133.2 million.

Cash flow is another point to watch. Operating cash flow was about ₹783 crore in FY26 after a weak ₹88 crore in FY25, and debt to equity is modest at 0.26. A stronger cash position gives Alembic room to fund new plants, research spending and US launches without stretching the balance sheet, which matters as research costs have been rising.

Growth Triggers in the Alembic Pharma Analyst Review 2027

  • Raised guidance: FY27 revenue growth now seen at 20% to 25%, up from mid-teens.
  • US launches: new products drove 77% US growth.
  • API momentum: 39% growth with at least high-teens expected for FY27.
  • India recovery: branded growth of 14%, above its past trend.
  • Margin gains: EBITDA margin at 22% supports the Alembic Pharma share price target 2027 case.

Key Risks in the Alembic Pharma Analyst Review 2027

  • Exclusivity ending: bosutinib's 180-day window closes in November 2026.
  • US price erosion: generic prices fall as more rivals launch.
  • Regulatory risk: US FDA inspections of plants.
  • Stock above targets: the last named target is well below the price.
  • High base: a record quarter sets a tough comparison, a caution in the Alembic Pharma analyst review 2027.

Compare Alembic Pharma With Other Pharma Stocks on the Univest Screener

Alembic Pharma Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (18 Nov 2026 close) ₹1,044.35
52-Week High / Low ₹1,075.00 / ₹635.80
Market Capitalisation ₹20,512 crore
P/E (TTM) 24.4
Industry P/E 40.1
Price to Book 3.45
Return on Equity 14.2%
Debt to Equity 0.26
Dividend Yield 1.15%
FY26 Revenue / Net Profit ₹7,399 crore / ₹671 crore

The trailing P/E of about 24 is well below the industry figure of about 40, even after the rally. Against the Nifty Pharma index, that gap is the main valuation support in this Alembic Pharma analyst review 2027, though part of recent profit depends on exclusivity sales.

Shareholding Trend

Holder Sep 2025 Sep 2026 Change
Promoters 69.74% 69.87% Up 0.13 points
Foreign Investors (FII) 4.05% 4.54% Up 0.49 points
Domestic Institutions (DII) 16.30% 15.43% Down 0.87 points
Public 9.92% 10.15% Up 0.23 points

The promoter group holds about 69.9%, through Nirayu Private Limited at 35.8% and listed group company Alembic Ltd at 28.5%. Stable holdings are a neutral point in the Alembic Pharma analyst review 2027.

Univest iOS App

Univest Android App

What to Watch After the Alembic Pharma Analyst Review 2027

  • US sales after exclusivity: how revenue holds once bosutinib faces rivals.
  • Guidance delivery: tracking against 20% to 25% FY27 growth.
  • Margins: EBITDA margin near 22%.
  • FDA updates: plant inspection outcomes.
  • New broker notes: fresh targets would reset the Alembic Pharma share price target 2027 view.

Final Word on the Alembic Pharma Analyst Review 2027

The Alembic Pharma analyst review 2027 shows a record quarter, with profit up 81%, every segment growing and guidance raised to 20% to 25%. The stock has moved well past the last named target, and the end of bosutinib exclusivity is the key near-term test.

The Alembic Pharma stock outlook 2027 depends on US sales after exclusivity, steady India growth and margins. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Alembic Pharma analyst review 2027 show?

It shows a record quarter. Q2 FY27 revenue rose 36% to ₹2,603 crore and profit rose 81% to ₹335 crore. EBITDA margin improved to 22% from 17%.

What is the Alembic Pharma share price target 2027 from brokerages?

Motilal Oswal had a Neutral rating with an ₹845 target on 4 August 2026. The stock closed at ₹1,044.35 on 18 November 2026, well above that level. We could not verify a named target issued after the Q2 results.

Why did Alembic Pharma profit jump in Q2 FY27?

US business revenue grew 77% to ₹910 crore on new launches including bosutinib. API grew 39% and India branded grew 14%. EBITDA margin widened by about 5 points.

What is bosutinib and why does it matter for Alembic Pharma?

Bosutinib is a cancer drug where Alembic had 180-day US exclusivity on two strengths until November 2026. Exclusivity allows higher prices before rivals launch. Management built some normalisation into its raised 20% to 25% guidance.

Is Alembic Pharma stock expensive based on the Alembic Pharma analyst review 2027?

The trailing P/E is about 24 against an industry P/E of about 40. Price to book is about 3.45. Part of recent profit depends on exclusivity sales that will fade.

What risks does the Alembic Pharma analyst review 2027 highlight?

The main risks are the end of bosutinib exclusivity, US price erosion and FDA inspections. The stock trades about 24% above Motilal Oswal's ₹845 target. The record quarter also sets a high base.

What should investors track after the Alembic Pharma analyst review 2027?

Track US sales once exclusivity ends and progress against 20% to 25% FY27 growth guidance. Watch EBITDA margin near 22%. New broker targets after the results also matter.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down